Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cognition Therapeutics Inc

CGTX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.01

▼ -2.88%

Market Cap $96.04M · Vol 98.57K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$96.04M

Micro Cap

Div Yield

N/A

EPS Growth

+1.04%

YoY

RSI (14)

56.18

Momentum

Beta

1.81

vs Market

52W High

$3.83

73.59% below

52W Low

$0.55

83.47% above

Volume

98.57K

Avg 144.14K

P/B

3.50

Price-to-book

ROE

N/A

Return on equity

Free Float

98.71%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Cognition Therapeutics Inc (CGTX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CGTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.48%

+0.00%

-15.83%

-9.82%

YTD

-25.19%

-39.16%

-31.76%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-23,487,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-59.75% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.50
P/FCF	N/A
EPS Growth	+1.04%
Outstanding Shares	95.09M

Technical Indicators

50-Day SMA	$1.10
200-Day SMA	$1.24
RSI (14)	56.18
Beta	1.81
52-Week High	$3.83
52-Week Low	$0.55

Volume Today	98.57K
Avg Daily Volume (30D)	144.14K
Relative Volume	0.68x
Volatility (10D)	75.49
Volatility (30D)	65.17
Free Float	98.71%

Analyst Consensus

BUY

Current Price $1.01

Mean Target $3.33

52W Low$0.55 52W High$3.83

Current

Target

$0.55 $3.83

Current Analyst target

+230.03% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V0GFB9

ISINUS19243B1026

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.